ArticleArchives of virology2017
Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication.
Article in Archives of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Flavour chemistry and metabolic engineering of microbial synthetic pyrazines: decoding the path to green manufacturing of food aroma components.Current research in food science · 2025Review
- Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen.Microorganisms · 2023Article
- Facile Synthesis of 5-Aryl-Molecules (Basel, Switzerland) · 2021Article
- Preliminary investigation of drug impurities associated with the anti-influenza drug Favipiravir - An insilico approach.Computational & theoretical chemistry · 2021Article
- Article
- An overview of the current medical literature on Zika virus.Biophysical reviews · 2020Article
- Article
- Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Antiviral efficacy of favipiravir against canine distemper virus infection in vitro.BMC veterinary research · 2019Article
- Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Antiviral Agents in Development for Zika Virus Infections.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Development of Small-Molecule Inhibitors Against Zika Virus Infection.Frontiers in microbiology · 2019Review
- Structure and function of Zika virus NS5 protein: perspectives for drug design.Cellular and molecular life sciences : CMLS · 2018Review
- Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.Viruses · 2018Article
- Understanding the Pathogenesis of Zika Virus Infection Using Animal Models.Immune network · 2017Review
- Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives.Frontiers in microbiology · 2017Review
- Article
- Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.Microbes and infectionReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Since 2015, 69 countries and territories have reported evidence of vector-borne Zika virus (ZIKV) transmission. Currently, there are no effective licensed vaccines or drugs available for the treatment or prevention of ZIKV infection. We tested a series of compounds for their ability to inhibit ZIKV replication in cell culture. The compounds in T-705 (favipiravir) and T-1105 were found to have antiviral activity, suggesting that these compounds are promising candidates for further development as specific antiviral drugs against ZIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.